Cantor Fitzgerald Analysts Lower Earnings Estimates for PTCT

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Cantor Fitzgerald dropped their FY2026 earnings per share (EPS) estimates for PTC Therapeutics in a note issued to investors on Tuesday, July 29th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of ($4.36) for the year, down from their previous forecast of ($3.22). Cantor Fitzgerald has a “Overweight” rating and a $120.00 price objective on the stock. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

A number of other research analysts have also commented on the stock. Wall Street Zen lowered shares of PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 16th. Robert W. Baird lowered their price target on PTC Therapeutics from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. Truist Financial upped their price target on PTC Therapeutics from $80.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. decreased their price objective on PTC Therapeutics from $75.00 to $67.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. Finally, Barclays boosted their price objective on PTC Therapeutics from $42.00 to $46.00 and gave the company an “equal weight” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $69.38.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $52.11 on Thursday. The company has a market cap of $4.13 billion, a PE ratio of 8.00 and a beta of 0.50. The firm has a fifty day moving average price of $49.08 and a two-hundred day moving average price of $48.63. PTC Therapeutics has a fifty-two week low of $29.01 and a fifty-two week high of $58.38.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, beating the consensus estimate of $0.85 by $9.19. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The company had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $437.16 million. During the same period in the prior year, the business earned ($1.20) earnings per share. PTC Therapeutics’s revenue for the quarter was down 9.6% compared to the same quarter last year.

Institutional Trading of PTC Therapeutics

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of PTC Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 9,178,822 shares of the biopharmaceutical company’s stock worth $414,332,000 after acquiring an additional 53,688 shares in the last quarter. Wellington Management Group LLP raised its position in PTC Therapeutics by 13.2% in the 1st quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company’s stock valued at $276,161,000 after purchasing an additional 632,049 shares during the last quarter. Toronto Dominion Bank acquired a new position in PTC Therapeutics in the fourth quarter worth $148,363,000. Janus Henderson Group PLC boosted its stake in PTC Therapeutics by 24.4% in the fourth quarter. Janus Henderson Group PLC now owns 2,325,915 shares of the biopharmaceutical company’s stock worth $105,015,000 after purchasing an additional 455,698 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its holdings in shares of PTC Therapeutics by 45.3% during the first quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company’s stock worth $77,084,000 after purchasing an additional 471,586 shares during the last quarter.

Insider Buying and Selling at PTC Therapeutics

In related news, CFO Pierre Gravier sold 2,516 shares of PTC Therapeutics stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total transaction of $124,441.36. Following the completion of the transaction, the chief financial officer directly owned 71,920 shares of the company’s stock, valued at $3,557,163.20. This trade represents a 3.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Mark Elliott Boulding sold 1,929 shares of the business’s stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $46.18, for a total transaction of $89,081.22. Following the completion of the transaction, the vice president owned 103,901 shares in the company, valued at approximately $4,798,148.18. This trade represents a 1.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,328 shares of company stock valued at $254,158 over the last quarter. Corporate insiders own 5.50% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.